Meeting
2017 ASCO Annual Meeting
Combination immunotherapy with IDO vaccine and PD-1 inhibitors in advanced NSCLC.
Authors
Anders Mellemgaard
Herlev University Hospital, Herlev, Denmark
Anders Mellemgaard , Lotte engel-Norregaard , Mads Hald Andersen , Mai-Britt Zocca , inge Marie Svane
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Developmental Therapeutics—Clinical Pharmacology and Experimental Therapeutics
Track
Developmental Therapeutics and Translational Research
Sub Track
Other Novel Agents
Citation
J Clin Oncol 35, 2017 (suppl; abstr TPS2610)
DOI
10.1200/JCO.2017.35.15_suppl.TPS2610
Abstract #
TPS2610
Poster Bd #
95a
Abstract Disclosures
Similar Posters
Poster
2018 ASCO-SITC Clinical Immuno-Oncology Symposium
Efficacy of immune-checkpoint inhibitors (ICI) in non-small cell lung cancer (NSCLC) patients harboring activating molecular alterations.
First Author: Laurent Mhanna
Poster
2023 ASCO Annual Meeting
Exploring the potential of combination immune checkpoint strategies in non-small cell lung cancer (NSCLC).
First Author: Aakash Desai
Poster
2021 Gastrointestinal Cancers Symposium
Response to PD-1 and PD-L1 based immunotherapy in MSS advanced colorectal cancer is impacted by metastatic disease sites.
First Author: Marwan Fakih
Poster
2020 ASCO Virtual Scientific Program
A phase II, open-label study of tomivosertib (eFT508) added on to continued checkpoint inhibitor therapy in patients (pts) with insufficient response to single-agent treatment.
First Author: Anthony B. El-Khoueiry